Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netivudine vs Acyclovir for Localized Herpes Zoster in Immunocompromised Patients
NCT00002315Phase 3Completed
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of netivudine in herpes zoster (HZ) (2 arms), sponsored by GSK. Primary endpoint: Efficacy in treatment of localized herpes zoster at 14 days. Status: completed.
02
Drugs
netivudine
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT00002315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002315.